Physician profile
Robin Dailey
NPI 1265893051
$13,510.28
in general payments reported to CMS, 2019-2025
42 companies · $2,741 in 2025
The $2,741 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,330 · 2022: $2,628 · 2023: $2,940 · 2024: $2,871 · 2025: $2,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,551.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,447.82 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,722.30 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $1,422.25 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,241.72 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,041.77 | 2021-2025 | |
| Glaxosmithkline, LLC. | $867.42 | 2021-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $602.42 | 2021-2025 | Jardiance, Tradjenta |
| Dexcom, INC. | $563.31 | 2021-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $430.20 | 2023-2025 | Gemtesa |
| Axsome Therapeutics, INC. | $399.57 | 2023-2025 | Auvelity |
| Abbott Laboratories | $371.44 | 2023-2025 | Freestyle Libre 3, Freestyle Libre, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $307.94 | 2022-2025 | |
| Amgen INC. | $294.25 | 2021-2024 | Repatha, Otezla |
| Mylan Specialty L.P. | $207.91 | 2021-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $171.89 | 2021-2023 | Verquvo, Belsomra, Vaxelis |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Dailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.